Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis

San Diego, CA, December 4, 1998 -- Signal Pharmaceuticals today announced the successful completion of preclinical studies demonstrating the ability of two series of compounds to safely and effectively inhibit bone resorption in animal models of osteoporosis. The drug leads belong to a new class of small molecule compounds termed selective estrogen receptor modulators (SERMs), also referred to as 'designer estrogens.' SERMs are designed to mimic the positive effects of estrogen by inhibiting bone loss in postmenopausal women, while avoiding some of estrogen's adverse effects such as increased risk of breast and uterine cancer. Moreover, studies have demonstrated that some SERMs, such as Zeneca's tamoxifen (NolvadexTM) and Eli Lilly's raloxifene (EvistaTM), also have anti-estrogenic effects and therefore can be effective in preventing and treating breast cancer. Signal researchers are presenting data from successful preclinical studies at the joint meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society being held in San Francisco, California, December 1-6.

Signal evaluated the efficacy of its novel SERMs in a rodent model of post-menopausal osteoporosis. Left untreated, these animals lose bone mass and eventually develop advanced stages of osteoporosis due to the loss of estrogen function. In the study, two series of drug leads were tested in parallel with estrogen and raloxifene for their ability to inhibit bone resorption. The study concluded that Signal's drug leads were twice as effective as raloxifene in preventing bone loss, at doses equal or less than raloxifene's therapeutic dose. In a separate study, these compounds also demonstrated superior safety, when compared with raloxifene, tamoxifen and estrogen, with regard to potential cancer risks in reproductive tissues. These drugs, if successfully developed, would provide clinicians with an alternative, non-estrogen treatment for osteoporosis

Contact: Neil Cohen
415-677-4455 x205
Noonan/Russo Communications

Page: 1 2 3 4

Related medicine news :

1. Signal identified that enables malarial parasites to target blood cells
2. Signaling pathway may be key to understanding roots of hypertension
3. Mouse study: Signal overload in Alzheimer brains
4. Neurobiologists Show How The Brain Processes Signals From Pheromones
5. Psychiatric Symptoms May Signal Brain Damage From Diet Pills
6. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
7. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
8. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
9. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
10. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
11. Pharmaceuticals and personal care products

Post Your Comments:

(Date:10/16/2018)... ... October 16, 2018 , ... With a petition (case CJ-2018-04177) filed ... McLain PLLC joins a series of lawsuits filed in states around the country against ... Massage Envy locations by Massage Envy’s massage therapists. , This lawsuit alleges that ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... its mission to provide simple, easy-to-use software for biopharma companies. By pairing the ... quickly answer those crucial resourcing questions without spending millions of dollars implementing a ...
(Date:10/16/2018)... Va. (PRWEB) , ... October 16, 2018 , ... ... Oct. 23-25, 2018 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit , The 13th Annual ... last year’s Inspections Summit that it sometimes feels difficult to keep up. The ...
(Date:10/16/2018)... Maine (PRWEB) , ... October 15, 2018 , ... ... Fluids product line, VALIDATE® Body Fluids, Order Number 205bf, for easier linearity and ... assist in the documentation of linearity, calibration verification and verification of the reportable ...
(Date:10/16/2018)... ... October 16, 2018 , ... AutismOne, ... host the proceedings of the 4th Annual International HPV Vaccine Education Symposium. , ... Wednesday, May 22, 2019, through Friday, May 24, 2019, with a keynote address ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... ... October 16, 2018 , ... Association Gloves & Supplies, ... alliance with The Dentists Supply Company (TDSC). TDSC operates an online ... catalog of dental supplies through tdsc.com. This strategic alliance enhances the value proposition ...
(Date:10/16/2018)... , ... October 16, 2018 , ... Cameras and monitoring ... of the home where safety plays a key role in a family’s health and ... of “Today’s Homeowner” TV hosted a “Safe At Home” satellite media event today. ...
(Date:10/16/2018)... ... October 16, 2018 , ... The iaedp™ Foundation, ... group of healthcare treatment providers who treat the full spectrum of eating disorder ... live, two-day, 12-hour track at Symposium 2019. The courses are regularly offered ...
Breaking Medicine Technology:
Cached News: